BioRestorative Therapies, Inc. (BRTX) Monday announced the presentation of a poster describing preliminary 26 and 52-week blinded data from the ongoing Phase 2 clinical trial of its clinical candidate, BRTX-100, in subjects with chronic lumbar disc disease or cLDD.
BRTX-100 is a cell-based therapeutic engineered to target areas of the body that have little blood flow. The safety and efficacy of BRTX-100 in treating cLDD are being evaluated in Phase 2, a prospective, randomized, double-blinded, and controlled study.
In the pre-market session, shares are gaining more than 21 percent at $3.36 on a volume of 1,078,507.
The poster was presented yesterday at the Orthopaedic Research Society 2024 Annual Meeting.
The clinical-stage company focused on stem cell-based therapies said the previous clinical studies have demonstrated that the harsh microenvironment of the disc could impact cell dose viability and result in a non-efficacious or the worsening of clinical outcomes.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.